<DOC>
	<DOCNO>NCT00002674</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Bone marrow transplantation may able replace immune cell destroy chemotherapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow G-CSF peripheral stem cell transplantation treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy MCE ( mitoxantrone/cytarabine/etoposide ) follow granulocyte colony-stimulating factor mobilize peripheral blood stem cell ( PBSC ) patient chronic myeloid leukemia ( CML ) . II . Evaluate toxicity regimen . III . Evaluate cytoreductive effect regimen CML determine ability mobilize Philadelphia chromosome-negative PBSC . IV . Assess time peak CD34+ CD34+/CD38- cell concentration peripheral blood patient treat regimen . OUTLINE : The follow acronym use : ARA-C Cytarabine , NSC-63878 DHAD Mitoxantrone , NSC-301739 G-CSF Granulocyte Colony-Stimulating Factor ( source specify ) HU Hydroxyurea , NSC-32065 MCE DHAD/ARA-C/VP-16 VP-16 Etoposide , NSC-141540 Single-Agent Cytoreduction follow 3-Drug Combination Chemotherapy/Stem Cell Mobilization . HU ; follow MCE ; G-CSF . PROJECTED ACCRUAL : 30 patient enter 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Philadelphia chromosomepositive chronic myeloid leukemia ( CML ) chronic accelerate phase Ineligible allograft protocol available HLAmatched sibling marrow donor No patient age 55 consent unrelated donor search unless : Search unsuccessful 6 month unlikely donor find Transplant unrelated donor decline No history CML blast crisis No grade III/IV myelofibrosis PATIENT CHARACTERISTICS : Age : Over 17 66 Performance status : Not specify Life expectancy : No limitation disease leukemia Other : No hepatic , renal , pulmonary , cardiac dysfunction would preclude transplant preparative regimen No HIV antibody No active infection PRIOR CONCURRENT THERAPY : At least 1 month since interferon</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>